Want to see KR:003120 full AI Analyst Report?
Top Page
ILSUNG IS CO., LTD.
(003120)
Select Model
Select Model
Rating:66Neutral
Price Target:
₩23,328.00
Action:N/A
Date:10/28/26
The score is driven primarily by solid financial footing (very low leverage) and strong TTM revenue growth, tempered by ongoing operating losses, uneven cash-flow history, and earnings volatility. Technical signals are mixed/neutral, and valuation is held back by a high P/E despite an attractive dividend yield.
Positive Factors
Very low leverage
Minimal debt materially reduces financial risk and interest burden, giving ILSUNG IS greater flexibility to withstand operating volatility. A conservative capital structure also preserves capacity to fund operations or pursue growth without relying heavily on refinancing or additional borrowing.
Negative Factors
Persistent operating losses
Operating losses show that revenue and gross profit are not yet covering the company’s operating cost base. Until this gap closes, growth may not translate into dependable operating earnings, limiting the durability of profitability and weakening the benefit of the company’s otherwise strong capitalization.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage
Minimal debt materially reduces financial risk and interest burden, giving ILSUNG IS greater flexibility to withstand operating volatility. A conservative capital structure also preserves capacity to fund operations or pursue growth without relying heavily on refinancing or additional borrowing.
Read all positive factors
ILSUNG IS CO., LTD. (003120) vs. SPDR S&P 500 ETF (SPY)
Market Cap
₩261.13B
Dividend Yield5.59%
Average Volume (3M)4.46K
Price to Earnings (P/E)37.6
Beta (1Y)0.17
Revenue Growth-5.16%
EPS Growth-53.05%
CountryKR
Employees224
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)571.11
Shares Outstanding13,300,000
10 Day Avg. Volume2,966
30 Day Avg. Volume4,458
Financial Highlights & Ratios
PEG Ratio-1.41
Price to Book (P/B)0.75
Price to Sales (P/S)4.51
P/FCF Ratio19.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ILSUNG IS CO., LTD. Business Overview & Revenue Model
Company Description
Ilsung Is Co., Ltd. is a South Korean pharmaceutical company established in 1961. The company specializes in the research, development, and manufacturing of medicines, with a historical focus on antibiotics. It also has products in areas such as c...
ILSUNG IS CO., LTD. Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
88
Very Positive
Cash Flow
60
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 65.22B | 64.29B | 69.02B | 78.05B | 61.25B | 42.09B |
| Gross Profit | 27.42B | 27.06B | 27.05B | 34.72B | 27.94B | 16.14B |
| EBITDA | -3.24B | -2.84B | 14.59B | -18.24B | 145.36B | 1.56B |
| Net Income | 5.54B | 1.17B | 13.09B | -20.94B | 108.67B | -1.37B |
Balance Sheet | ||||||
| Total Assets | 394.04B | 403.01B | 396.88B | 419.19B | 498.74B | 371.38B |
| Cash, Cash Equivalents and Short-Term Investments | 211.97B | 225.93B | 222.29B | 235.42B | 299.93B | 64.09B |
| Total Debt | 122.99M | 132.17M | 161.82M | 238.13M | 274.35M | 181.07M |
| Total Liabilities | 14.27B | 16.67B | 11.75B | 36.44B | 49.75B | 25.47B |
| Stockholders Equity | 379.77B | 386.34B | 385.13B | 382.75B | 449.00B | 345.91B |
Cash Flow | ||||||
| Free Cash Flow | 5.43B | 15.14B | -16.34B | -49.20B | -101.46B | -6.91B |
| Operating Cash Flow | 7.07B | 17.28B | -4.26B | -41.47B | -38.97B | 5.70B |
| Investing Cash Flow | -16.52B | -8.64B | -35.54B | -26.95B | 266.83B | 10.43B |
| Financing Cash Flow | -385.54M | 1.04B | -10.30B | -44.52B | -5.74B | -1.48B |
ILSUNG IS CO., LTD. Technical Analysis
Negative
―
Price Trends
21398.00
Positive
20599.10
Positive
21509.00
Negative
Market Momentum
14.52
Positive
45.14
Neutral
55.07
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:003120, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 21847.50, equal to the 50-day MA of 21398.00, and equal to the 200-day MA of 21509.00, indicating a neutral trend. The MACD of 14.52 indicates Positive momentum. The RSI at 45.14 is Neutral, neither overbought nor oversold. The STOCH value of 55.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:003120.
ILSUNG IS CO., LTD. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ₩271.92B | 3.23 | ― | 5.47% | 10.18% | 149.93% | |
71 Outperform | ₩243.17B | 3.39 | ― | 3.64% | 4.13% | 116.32% | |
66 Neutral | ₩261.13B | 37.56 | ― | 5.59% | -5.16% | -53.05% | |
58 Neutral | ₩198.48B | 5.07 | ― | 2.80% | 11.64% | -4.94% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | ₩299.64B | 12.56 | ― | 1.57% | 5.50% | -26.11% | |
40 Underperform | ₩173.93B | -28.12 | ― | ― | 0.60% | -6964.46% |
* General Sector Average
KR:003120
ILSUNG IS CO., LTD.
21,450.00
-484.51
-2.21%
KR:003520
YUNGJIN PHARM. CO. LTD
951.00
-1,089.00
-53.38%
KR:008490
Suheung Co. Ltd.
17,850.00
-9,106.65
-33.78%
KR:009290
Kwang Dong Pharmaceutical Co., Ltd.
6,370.00
705.94
12.46%
KR:033270
KOREA UNITED PHARM, INC.
16,760.00
-1,539.97
-8.42%
KR:096760
JW Holdings Corporation
3,930.00
841.00
27.23%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.